The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study
Authors:
- 1 January 1995
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 37 (1-2) , 173-178
Abstract
Paclitaxel is an important agent in the treatment of many common malignancies. Although the symptomatic peripheral neuropathy caused by this drug is its principal nonhematologic toxicity, little is known about the distribution of paclitaxel within the peripheral or central nervous system following systemic administration. In order to study paclitaxel's distribution in neural and extraneural tissues, adult Sprague-Dawley rats were sacrificed 2 h after a tail vein injection of [3H]-paclitaxel (0.03 mg/kg, 250 μCi/rat). Samples of lung, heart, liver, spleen, kidney, skeletal muscle, brain, spinal cord, dorsal root ganglion, and peripheral nerve were then removed and snap-frozen. These tissues were sectioned at 10 μm in a cryostat and exposed to autoradiography film for 2 weeks. The distribution and concentrations of [3H]-paclitaxel in plasma, urine and cerebrospinal fluid were also determined using liquid scintillation spectrometry. [3H]-Paclitaxel concentrations (and organ/plasma concentration ratios) in plasma, urine and cerebrospinal fluid were 2.6 nM (1), 38 nM (15) and 0.7 nM (0.3), respectively. A relatively homogeneous distribution of [3H]-paclitaxel was observed in liver [412 nM (151)], spleen [351 nM (133)], heart [319 nM (117)], lung [268 nM (93)] and muscle [69 nM (26)]. Higher concentrations of [3H]-paclitaxel were noted in the portal triads [869 nM (361)], glomeruli [797 nM (304)], and renal medulla [961 nM (363)], which may reflect biliary excretion and glomerular filtration. A high concentration of [3H]-paclitaxel was also noted in the choroid plexus [432 nM (167)], but [3H]-paclitaxel was not detected in the brain parenchyma, spinal cord, dorsal root ganglion, peripheral nerve, or the testicles. The pathogenesis of paclitaxelinduced neurotoxicity remains obscure given its limited distribution in the nervous system. In addition, these results suggest that systemically administered paclitaxel is not likely to be effective for the treatment of malignancies in the testes or the nervous system.Keywords
This publication has 26 references indexed in Scilit:
- Taxol NeuropathyArchives of Neurology, 1994
- Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group ResultsJNCI: Journal of the National Cancer Institute, 1993
- Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.Journal of Clinical Oncology, 1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI: Journal of the National Cancer Institute, 1991
- Nerve growth factor prevents toxic neuropathy in miceAnnals of Neurology, 1991
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI: Journal of the National Cancer Institute, 1990
- Taxol produces a predominantly sensory neuropathyNeurology, 1989
- Phase I trial of taxol in patients with advanced cancer.1987
- Regulation of the microenvironment of peripheral nerve: Role of the blood-nerve barrierProgress in Neurobiology, 1987
- Taxol stabilizes microtubules in mouse fibroblast cells.Proceedings of the National Academy of Sciences, 1980